President Of Green Cross To Step Down
The president of Green Cross of Japan has said that he will step down from his post in a move to take responsibility for Green Cross selling blood products infected with HIV (Marketletters passim), according to local reports. No date was given for when company president Takehiko Kawano's resignation would be effective, but it is likely to be after ongoing restructuring efforts by the firm show results, a company official said, according to one local report.
The company is expecting to make huge losses as a result of the financial settlement of lawsuits with hemophiliacs who were infected by HIV. Also, company sources are reported to have said that the firm is being adversely affected by a boycott of its products.
Furthermore, Green Cross is alleged to have told lies to its sales staff, in an edition of the company's in-house newsletter in 1984, about the safety of the blood products they were marketing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze